Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease

A pilot study of azithromycin treatment following percutaneous coronary rev ascularization procedures was performed to assess safety and the effect of azithromycin treatment on anti-Chlamydia pneumoniae antibody titres. Patien ts were randomized to a 1 month course of azithromycin (total dose of 8.0 g ) or placebo. Safety and compliance were assessed at 2 and 4 weeks and sero logical testing was performed on samples obtained at enrolment and at 6 mon ths post-enrolment. Azithromycin was well tolerated at this dose. No effect of treatment on antibody titres was demonstrated. These results support fu rther clinical trials to assess the effect of azithromycin treatment on car diovascular disease outcomes.